Nycomed Amersham, Neurochem to collaborate on Alzheimer's agents

Jul 18, 2001

Contrast developer Nycomed Amersham Imaging has signed an agreement with Canadian pharmaceutical firm Neurochem that could result in new products for detecting early signs of Alzheimer's disease.

Under the collaboration, Neurochem will review its library of clinical therapeutic compounds and identify molecules that bind to beta-amyloid, a key marker for Alzheimer's disease. Nycomed Amersham will then synthesize radiolabeled binding molecules to be used to detect Alzheimer's with diagnostic imaging tools.

The goal is to enable the early identification of amyloid plaques in the brains of Alzheimer's patients, before symptoms of the disease are observed.

By AuntMinnie.com staff writers
July 19, 2001
Related Reading

Wagner taps PET Alzheimer’s study as SNM 2001’s Image of the Year, June 26, 2001

PET, SPECT differ in Alzheimer's imaging, June 25, 2001

FDA approves Nycomed Amersham's EchoSeed, June 4, 2001

Nycomed, HSCA extend contract, May 31, 2001

Nycomed Amersham changes name to Amersham PLC, May 11, 2001

Nycomed gets sole-source TheraSeed deal from Premier, May 9, 2001

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$